<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <body>
  <table style="border: 1px solid black;">
   <caption/>
   <tr>
    <th style="border: 1px solid black;">First author (year) </th>
    <th style="border: 1px solid black;">Study type and quality (CONSORT/STROBE score) </th>
    <th style="border: 1px solid black;">Incidence (95% CI) </th>
    <th style="border: 1px solid black;">Main cancer class (chemotherapy) </th>
    <th style="border: 1px solid black;">Dose (mg/m ) ^{2} (mean or cumulative) </th>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Antonacopoulou (2009) </td>
    <td style="border: 1px solid black;">Prospective cohort </td>
    <td style="border: 1px solid black;">58.8% (42.2–75.3) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">— </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">^{*} </td>
    <td style="border: 1px solid black;">Prospective cohort (18/22) </td>
    <td style="border: 1px solid black;">61.5% (35.1–87.9) </td>
    <td style="border: 1px solid black;">Breast (paclitaxel) </td>
    <td style="border: 1px solid black;">1980 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Argyriou (2006) </td>
    <td style="border: 1px solid black;">Prospective cohort (19/22) </td>
    <td style="border: 1px solid black;">42.8% (16.9–68.7) </td>
    <td style="border: 1px solid black;">Lung (cisplatin) </td>
    <td style="border: 1px solid black;">720 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Argyriou (2007) [8] </td>
    <td style="border: 1px solid black;">Prospective cohort (19/22) </td>
    <td style="border: 1px solid black;">64% (45.2–82.8) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">1740 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Argyriou (2007) </td>
    <td style="border: 1px solid black;">Prospective cohort (19/22) </td>
    <td style="border: 1px solid black;">69.2% (44.1–94.3) </td>
    <td style="border: 1px solid black;">Multiple solid (cisplatin and paclitaxel) </td>
    <td style="border: 1px solid black;">126·7 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Argyriou (2012) </td>
    <td style="border: 1px solid black;">Prospective cohort (20/22) </td>
    <td style="border: 1px solid black;">83.3% (77.3–89.3) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">1646 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Argyriou (2013) </td>
    <td style="border: 1px solid black;">Prospective cohort (19/22) </td>
    <td style="border: 1px solid black;">84.5% (79.4–89.5) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">1651 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Attal (2009) </td>
    <td style="border: 1px solid black;">Prospective cohort (20/22) </td>
    <td style="border: 1px solid black;">66.6% (44.8–88.4) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">1278 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Baldwin (2012) </td>
    <td style="border: 1px solid black;">RCT (18/25) </td>
    <td style="border: 1px solid black;">67.2% (64.1–70.3) </td>
    <td style="border: 1px solid black;">Breast (paclitaxel) </td>
    <td style="border: 1px solid black;">— </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Cascinu (1995) </td>
    <td style="border: 1px solid black;">RCT (16/25) </td>
    <td style="border: 1px solid black;">64% (45.2–82.8) </td>
    <td style="border: 1px solid black;">Gastrointestinal (cisplatin) </td>
    <td style="border: 1px solid black;">— </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Cascinu (2002) </td>
    <td style="border: 1px solid black;">Prospective cohort (13/22) </td>
    <td style="border: 1px solid black;">78.9% (60.6–97.3) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">783 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Chaudhary (2008) </td>
    <td style="border: 1px solid black;">RCT (21/25) </td>
    <td style="border: 1px solid black;">96.2% (89.2–103) </td>
    <td style="border: 1px solid black;">Multiple myeloma (bortezomib and thalidomide) </td>
    <td style="border: 1px solid black;">36 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">^{†} </td>
    <td style="border: 1px solid black;">RCT (18/25) </td>
    <td style="border: 1px solid black;">46.7% (41.4–52.1) </td>
    <td style="border: 1px solid black;">Multiple myeloma (bortezomib) </td>
    <td style="border: 1px solid black;">38·4 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Dimopoulos (2011) </td>
    <td style="border: 1px solid black;">RCT (19/25) </td>
    <td style="border: 1px solid black;">12.1% (5.6–18·5) </td>
    <td style="border: 1px solid black;">Ovarian and lung (cisplatin) </td>
    <td style="border: 1px solid black;">379 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Gandara (1995) </td>
    <td style="border: 1px solid black;">Cross sectional cohort (21/22) </td>
    <td style="border: 1px solid black;">59.2% (40.7–77.8) </td>
    <td style="border: 1px solid black;">Breast (paclitaxel) </td>
    <td style="border: 1px solid black;">— </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">^{‡} </td>
    <td style="border: 1px solid black;">RCT (13/25) </td>
    <td style="border: 1px solid black;">20.1% (15.5–24.7) </td>
    <td style="border: 1px solid black;">Testicular (cisplatin and vincristine) </td>
    <td style="border: 1px solid black;">400 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Ghoreishi (2012) </td>
    <td style="border: 1px solid black;">RCT (20/25) </td>
    <td style="border: 1px solid black;">70% (53.6–86.4) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">763 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Glendenning (2010) </td>
    <td style="border: 1px solid black;">RCT (23/25) </td>
    <td style="border: 1px solid black;">93.7% (81.9–105) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">72·8 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">^{†} </td>
    <td style="border: 1px solid black;">Prospective cohort (14/22) </td>
    <td style="border: 1px solid black;">32.1% (29.1–34.9) </td>
    <td style="border: 1px solid black;">Multiple myeloma (thalidomide) </td>
    <td style="border: 1px solid black;">— </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Gobran (2013) </td>
    <td style="border: 1px solid black;">RCT (19/25) </td>
    <td style="border: 1px solid black;">19.6% (16.3–22.9) </td>
    <td style="border: 1px solid black;">(Vincristine) </td>
    <td style="border: 1px solid black;">— </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Ishibashi (2010) </td>
    <td style="border: 1px solid black;">Prospective cohort (16/22) </td>
    <td style="border: 1px solid black;">76% (64.1–87.8) </td>
    <td style="border: 1px solid black;">Lung (cisplatin and paclitaxel) </td>
    <td style="border: 1px solid black;">— </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Johnson (2011) </td>
    <td style="border: 1px solid black;">Randomised trial (15/24) </td>
    <td style="border: 1px solid black;">67·5% (59.2–75.8) </td>
    <td style="border: 1px solid black;">Gynecological (cisplatin) </td>
    <td style="border: 1px solid black;">— </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Kawakami (2012) </td>
    <td style="border: 1px solid black;">Randomised trial (11/24) </td>
    <td style="border: 1px solid black;">50% (25.5–74.5) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">1200 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">^{†} </td>
    <td style="border: 1px solid black;">Randomised trial (11/24) </td>
    <td style="border: 1px solid black;">90% (71.4–108) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">1200 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Kemp (1996) </td>
    <td style="border: 1px solid black;">Prospective cohort (14/22) </td>
    <td style="border: 1px solid black;">92.8% (79.3–106) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">772 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Krishnan (2005) </td>
    <td style="border: 1px solid black;">RCT (19/25) </td>
    <td style="border: 1px solid black;">85.7% (67.4–104) </td>
    <td style="border: 1px solid black;">Multiple solid (cisplatin) </td>
    <td style="border: 1px solid black;">420 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Lin (2006) </td>
    <td style="border: 1px solid black;">Randomised trial (13/24) </td>
    <td style="border: 1px solid black;">92.8% (79.4–106) </td>
    <td style="border: 1px solid black;">Breast (paclitaxel) </td>
    <td style="border: 1px solid black;">1744 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Milla (2009) </td>
    <td style="border: 1px solid black;">Prospective cohort (15/22) </td>
    <td style="border: 1px solid black;">41.6% (21.9–61.4) </td>
    <td style="border: 1px solid black;">Multiple solid (cisplatin) </td>
    <td style="border: 1px solid black;">450 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Pace (2003) </td>
    <td style="border: 1px solid black;">RCT (12/25) </td>
    <td style="border: 1px solid black;">13.5% (2.5–24.5) </td>
    <td style="border: 1px solid black;">Multiple solid (cisplatin) </td>
    <td style="border: 1px solid black;">401 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Pace (2007) </td>
    <td style="border: 1px solid black;">Prospective cohort (9/22) </td>
    <td style="border: 1px solid black;">96% (88.3–103) </td>
    <td style="border: 1px solid black;">Multiple myeloma (thalidomide) </td>
    <td style="border: 1px solid black;">18 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Pace (2010) </td>
    <td style="border: 1px solid black;">Prospective cohort (16/22) </td>
    <td style="border: 1px solid black;">41.6% (13.7–69.5) </td>
    <td style="border: 1px solid black;">Gynecological (cisplatin) </td>
    <td style="border: 1px solid black;">416 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Planting (1999) </td>
    <td style="border: 1px solid black;">17.2% (3.4–30.9) </td>
    <td style="border: 1px solid black;">Testicular (cisplatin) </td>
    <td style="border: 1px solid black;">— </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Plasmati (2002) </td>
    <td style="border: 1px solid black;">40.6% (30.8–50.4) </td>
    <td style="border: 1px solid black;">Colorectal (oxaliplatin) </td>
    <td style="border: 1px solid black;">935 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Van der Hoop (1999) </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Von Schlippe (2001) </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Won (2012) </td>
   </tr>
  </table>
 </body>
</html>
